Home Search
hepa - search results
If you're not happy with the results, please do another search
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.
Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today.
We're beginning to believe (and...
News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10.
Of course, approval news is the ultimate "as huge as it gets" news.
But at this stage...
Remember President Trump Taking Dexamethasone? Hepion’s (HEPA) CRV431 demonstrated reduced lung inflammation and damage...
Hepion (HEPA) Announces FDA Clearance of IND Application for CRV431 for COVID-19
Adding Hepion Pharma (HEPA) $1.73 to Watch List.
Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here?
Oh my…and Oh boy....
Hepion Pharma (HEPA): News Archive
UPDATED CONTINUOUSLY..
12/31/2020: News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10.
12/23/2020: Remember...
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll...
ThinkEquity Investor Conference (NYC), Wednesday October 26th.
ThinkEquity is a boutique investment bank run by experienced professionals that have worked together for over a...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
Latest article
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
